| Name | Title | Contact Details |
|---|
Medicilon Inc. is a prominent Contract Research Organization (CRO) based in Shanghai, China, established in 2004. The company specializes in comprehensive preclinical drug discovery and development services, helping pharmaceutical and biotech clients progress from concept to Investigational New Drug (IND) filing. With over 300,000 square feet of lab space and a team of more than 2,400 scientists, Medicilon is recognized for its expertise and innovation in the field. The company offers a wide range of services, including drug discovery, CMC development, and preclinical research. Their capabilities encompass precision chemical synthesis, GMP-compliant API manufacturing, and extensive pharmacology and toxicology studies. Medicilon adheres to FDA methodologies and international standards, ensuring regulatory compliance throughout the development process. With a focus on client-centric solutions, Medicilon has successfully conducted over 10,000 studies and serves more than 2,000 clients worldwide, emphasizing long-term partnerships and support for drug development programs.
NatureWorks LLC is a stand-alone company wholly owned by Cargill. Dedicated to meeting the world's needs today without compromising the earth's ability to meet the needs of tomorrow, NatureWorks LLC is the first company to offer a family of commercially
iCyt is a profitable, innovative, bioscience technology company that will contribute to its community by: delivering novel cell measurement and handling technologies that enable our clients to create important new healthcare and agriculture
Avelas Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities. Alexion has more than 3,000 employees serving patients in 50 countries. Our global headquarters and research operations are based in New Haven, Connecticut and our EMEA headquarters are in Zürich, Switzerland. We also have global supply chain and operations headquarters in Ireland, manufacturing facilities in the United States, and local and regional operations in countries around the world. Alexion was ranked number 5 by Science magazine in its Top Employer Survey and has also been ranked as one of the top companies on the Forbes "World`s Most Innovative Companies" list every year since 2012.